Moderating Effects and Maintenance of Lung Cancer Cellular Immune Functions by CIK Cell Therapy

  • Jin, Cong-Guo (Cancer Research Institute of Yunnan Cancer Hospital (The 3rd Affiliated Hospital of Kunming Medical University)) ;
  • Chen, Xiao-Qun (Cancer Research Institute of Yunnan Cancer Hospital (The 3rd Affiliated Hospital of Kunming Medical University)) ;
  • Li, Jia (Cancer Research Institute of Yunnan Cancer Hospital (The 3rd Affiliated Hospital of Kunming Medical University)) ;
  • Wu, Zhi-Pin (Cancer Research Institute of Yunnan Cancer Hospital (The 3rd Affiliated Hospital of Kunming Medical University)) ;
  • Liu, Xin (Cancer Research Institute of Yunnan Cancer Hospital (The 3rd Affiliated Hospital of Kunming Medical University)) ;
  • Wang, Xi-Cai (Cancer Research Institute of Yunnan Cancer Hospital (The 3rd Affiliated Hospital of Kunming Medical University))
  • Published : 2013.06.30


Aims: To study the CIK cell treatment effects on regulation of cellular immune function disorders in patients with lung cancer, and to analyze the time characteristics. Methods: Cellular immune function was assessed by FCM, and patients with functional disorders were randomly divided into two groups, one given CIK cell therapy within 18 months (5 courses) and the other the controls, which were followed up for 1 year with cellular immune functions tested once a month. Results: There were 5 types of cellular immunity, 4 of which are disorders; after CIK treatment, the improvement rate of the 4 groups were 79.1%, 70.8%, 76.0% and 70.0%, intergroup differences not being statistically significant (P=0.675), all significantly higher than in the control group (P=0.000). The median maintenance times for the 4 groups were 10.4 months (9.76-11.04), 8.4 months (7.86-8.94), 9.8 months (9.20-10.4) and 7.9 months (6.25-9.55), respectively. Conclusions: CIK cells were able to improve the immune functions of patients with lung cancer, the rate of improvement and maintenance time being related to the immune function before the treatment and CIK-cell-therapy courses.


  1. Bordon E, Henriquez-Hernandez LA, Lara PC (2011). Role of CD4 and CD8 T-lymphocytes, B-lymphocytes and Natural Killer cells in the prediction of radiation-induced late toxicity in cervical cancer patients. Int J Radiat Biol, 87, 424-31.
  2. Das S, Karim S, Datta Ray C (2007). Peripheral blood lymphocyte subpopulations in patients with cervical cancer. Int J Gynaecol Obstet, 98, 143-6.
  3. Holtl L, Rieser C, Papesh C, et al (1999). Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendntic cell. J Urol, 161, 777-82.
  4. Hongeng S, Petvises S, Worapongpaiboon S, et al (2003). Generation of CD3+CD56+ cytokine induced killer cells and their invitro cytotoxicity against pediatric cancer cells. Int J Hematol, 77, 175-9.
  5. Hsu HS, Huang PI, Chang YL, et al (2011). Cucurbitacin i inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells. Cancer, 117, 2970-85.
  6. Kim YJ, Lim J, Kang JS, et al (2010). Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells. Arch Pharm Res, 33, 1789-95.
  7. Kuss I, Hathway B, Ferris RL, et al (2004). Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res, 10, 3755-62.
  8. Levina V, Marrangoni A, Wan g T, et al (2010). Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop. Cancer Res, 70, 338-46.
  9. Li R, Wang C, Liu L, et al (2012). Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother, 61, 2125-33.
  10. Mendez R, Ruiz-Cabello F, Rodriguez T, et al(2007). Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherap. Cancer Immunol Immunother, 56, 88-94.
  11. Baas P, Belderbos J SA, van den Heuvel M (2011). Chemoradiation therapy in n on small cell lung cancer. Curr Opin Oncol, 23, 140-9.
  12. Blattman JN, Greenberg PD (2004). Cancer immunotherapy: a treatment for the masses. Science, 305, 200-5.
  13. Shepherd FA, Douillard JY and Blumenschein GR Jr (2011). Immunotherapy for non-small cell lung cancer: novel approaches to improve patient outcome. J Thorac Oncol, 6, 1763-73.
  14. Shi M, Zhang B, Tang ZR, et al (2004). Autologous cytokine induced killer(CIK)cell therapy in clinical trial phaseⅠissafe in patients with primary hepatocellular carcinoma. World J Gastroenterol, 10, 1146-51.
  15. Sievers E, Albers P, Schmidt-Wolf IG , et al (2004). Telomerase pulsed dendritic cells for immunotherapy for renal cell carcinoma. J Urol, 171, 114-9.
  16. Urbanska K, Lanitis E, Poussin M, et al (2012). A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res, 72 ,1844-52.
  17. Wang H, Zhou FJ, Wang QJ (2006). Efficacy of autologous renal tumor cell lysate- loaded dendritic cell vaccine in combination with cytokine- induced killer cells on advanced renal cell carcinoma- - a report of ten cases. Ai Zheng, 25, 625-30.
  18. Wongkajornsilp A, Somchitprasert T, Butraporn R, et al (2009). Human cytokine- induced killer cells specifically infiltrated and etarded the growth of the inoculated human cholangiocarcinoma cells in SCID mice. Cancer Invest, 27, 140-8.
  19. Wu F, Wang ZB, Lu P, et al (2004). Activated anti-tumor immunity in cancer patients after high intensity focused ultrasound ablation. Ultrasound Med Biol, 30, 1217-22.
  20. Xu Y, Liu LJ, Gao JM, et al (2010). Specific Anti- tumor Biological Activity of DCIK Cells. China Modern Doctor, 27, 360-2
  21. Zhang H, Zhao Q, Zuo LF, et al (2007). The functional mechanism of CIK cell on ovarian carcinoma cell lines SKOV3/CDDP. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 23, 1167-9.

Cited by

  1. Induction of Indoleamine 2,3-dioxygenase (IDO) Enzymatic Activity Contributes to Interferon-Gamma Induced Apoptosis and Death Receptor 5 Expression in Human Non-small Cell Lung Cancer Cells vol.15, pp.18, 2014,
  2. T-cell-associated cellular immunotherapy for lung cancer vol.141, pp.7, 2015,
  3. Advances in Immune Therapy for Non Small Cell Lung Cancer vol.06, pp.01, 2016,
  4. Cell-based immunotherapy with cytokine-induced killer (CIK) cells: From preparation and testing to clinical application vol.13, pp.6, 2017,
  5. Effect of cytokine-induced killer cells on immune function in patients with lung cancer vol.11, pp.4, 2016,